Clinical trials: Shingles
Varicella
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.
- Trial name
- NCT03843632
- Testing
- VARIVAX™
- Where
- 5 sites in Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella (Chicken Pox)
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.
- Trial name
- NCT02367638
- Testing
- MG1111, VARIVAX
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Rubella, Varicella
Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine
Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration…
- Conditions
- Rubella, Varicella, Mumps, Measles
- Trial name
- NCT00406211
- Testing
- MMRV, MMR (Priorix®), Varicella (Varilrix®)
- Where
- 41 sites in Austria, Germany
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Rubella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Measles, Rubella, Mumps, Varicella
- Trial name
- NCT00127010
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 48 sites in Belgium, Germany and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of…
- Trial name
- NCT05219253
- Testing
- HZ/su
- Where
- 9 sites in India
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
- Trial name
- NCT05422508
- Testing
- MG1111 (BARICELA), VARIVAX, Suduvax
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox
Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
The purpose of this study is to observe the persistence of protection, duration of protection, safety and breakthrough infection rates afforded by live attenuated varicella vaccine in children over a 5-year period.
- Trial name
- NCT01982409
- Testing
- Live Attenuated Varicella Vaccine
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Changchun Changsheng Life Science and Technology Co., Ltd.
Herpes Zoster
Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 50 years.
- Trial name
- NCT01165177
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 274 sites in United States, Australia and 16 more
- Volunteers
- 16,165 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Postherpetic Neuralgia
Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo
The purpose of this study is to see if therapy with the drug pregabalin relieves pain during shingles compared with placebo. A placebo is an inactive substance.
- Trial name
- NCT00352651
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Persistence of Protection by Shingrix
The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people. Two vaccines are currently approved by the Food and Drug Administration (FDA) to prevent shingles.
- Trial name
- NCT04169009
- Testing
- Zostavax, Shingrix
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Herpes Zoster
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT01954251
- Testing
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Varicella
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX® (Varicella Virus Vaccine Live) manufactured with a new passage extension (PE34) process compared with the VARIVAX® 2016 commercial process.
- Trial name
- NCT03239873
- Testing
- VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®
- Where
- 37 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella
The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination
To investigate the safety, immunogenicity and immune effect of the Varicella vaccine after the 2nd dose vaccination in Chao yang district, Bei jing, since the 2nd varicella vaccination was promoted by Beijing Center for Disease…
- Trial name
- NCT01830283
- Testing
- varicella vaccine
- Where
- China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Herpes Zoster
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in…
- Trial name
- NCT01483378
- Testing
- Choosing to receive the vaccine
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health